系统性自身免疫性风湿病患者重度肺动脉高压相关因素:全国性研究
基于台湾2003–2017年全国数据,纳入系统性红斑狼疮、类风湿关节炎、系统性硬化症、皮肌炎/多肌炎和原发性干燥综合征患者,识别479例重度肺动脉高压(PAH)并按年龄、性别和索引年1:4匹配对照。条件logistic回归显示重度PAH与间质性肺病、充血性心力衰竭、瓣膜性心脏病及甲状腺疾病相关,与细颗粒物(p.m.2.5)暴露水平无关;使用糖皮质激素、生物制剂及多种免疫抑制剂与PAH风险升高相关。
要点
- 间质性肺病、充血性心力衰竭和瓣膜性心脏病与重度PAH风险显著相关。
- 糖皮质激素、生物制剂及环孢素、硫唑嘌呤、环磷酰胺、霉酚酸酯与PAH风险升高相关。
- 未发现p.m.2.5暴露水平与重度PAH相关。
核心结论
- 在系统性自身免疫性风湿病患者中识别出重度PAH的相关危险因素,为PAH风险分层提供依据。
研究设计与样本
- 基于台湾2003–2017年全国数据,纳入系统性红斑狼疮、类风湿关节炎、系统性硬化症、皮肌炎/多肌炎和原发性干燥综合征患者,识别479例重度PAH并按年龄、性别和索引年1:4匹配对照,采用条件logistic回归分析。
主要发现
- 重度PAH与间质性肺病(OR 8.57;95%CI 5.52,13.32)、充血性心力衰竭(OR 7.62;95%CI 5.02,11.55)、瓣膜性心脏病(OR 3.34;95%CI 2.03,5.50)高度相关,与甲状腺疾病轻度相关(OR 1.88;95%CI 1.18,3.00),与p.m.2.5暴露水平无关。
- 使用糖皮质激素(泼尼松等效剂量,mg/天,OR 1.03;95%CI 1.01,1.05)、生物制剂(OR 2.18;95%CI 1.15,4.12)及免疫抑制剂包括环孢素(OR 2.17;95%CI 1.31,3.59)、硫唑嘌呤(OR 1.96;95%CI 1.48,2.61)、环磷酰胺(OR 2.01;95%CI 1.30,3.11)、霉酚酸酯/霉酚酸(OR 2.42;95%CI 1.37,4.27)与PAH风险升高相关。
- 最高投保金额水平者(参照最低水平)PAH风险较低(OR 0.53;95%CI 0.34,0.83)。
临床怎么用
- 对系统性自身免疫性风湿病患者应评估间质性肺病、充血性心力衰竭、瓣膜性心脏病及甲状腺疾病等PAH相关因素以进行风险分层。
- 使用糖皮质激素、生物制剂或免疫抑制剂的患者需关注重度PAH风险。
局限性
- 原文未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the association of severe pulmonary arterial hypertension (PAH) with particulate matter <2.5 μm (p.m.2.5) and clinical data in patients with systemic autoimmune rheumatic diseases (SARDs). METHODS: We used the 2003-2017 nationwide data in Taiwan to identify patients with SARDs, including systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis, dermatomyositis/polymyositis and primary Sjögren's syndrome. We identified 479 cases with severe PAH and selected controls matched (1:4) for age, sex, and index year. We used conditional logistic regression analysis to determine factors associated with risks for severe PAH shown as odds ratios (ORs) with 95% confidence intervals (CIs). RESULTS: We found that severe PAH was highly associated with interstitial lung disease (OR, 8.57; 95% CI: 5.52, 13.32), congestive heart failure (OR, 7.62; 95% CI: 5.02, 11.55), valvular heart disease (OR, 3.34; 95% CI: 2.03, 5.50) and slightly associated with thyroid diseases (OR, 1.88; 95% CI: 1.18, 3.00), but not the level of exposure to p.m.2.5. Increased risk for PAH was found in patients receiving corticosteroid (prednisolone equivalent dosage, mg/day, OR, 1.03; 95% CI: 1.01, 1.05), biologics (OR, 2.18; 95% CI: 1.15, 4.12) as well as immunosuppressants, including ciclosporin (OR, 2.17; 95% CI: 1.31, 3.59), azathioprine (OR, 1.96; 95% CI: 1.48, 2.61), cyclophosphamide (OR, 2.01; 95% CI: 1.30, 3.11) and mycophenolate mofetil/mycophenolic acid (OR, 2.42; 95% CI: 1.37, 4.27), and those with the highest level of insured amount (reference, lowest level; OR, 0.53; 95% CI: 0.34, 0.83). CONCLUSION: The population-based study identified risks for severe PAH in patients with SARDs, and these findings provide evidence for PAH risk stratification in patients with SARDs.
引用
- Chen HH, Lin CH, Hsieh TY, et al. Factors associated with incident severe pulmonary arterial hypertension in systemic autoimmune rheumatic diseases: a nationwide study. Rheumatology (Oxford). 2021. PMID: 33547781. doi:10.1093/rheumatology/keab118
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。